Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Rezafungin in Pediatric Subjects
NCT05534529Phase 1Terminated
- Sponsor
- Mundipharma
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of rezafungin in invasive fungal infection (IFI), sponsored by Mundipharma. Primary endpoints: Maximum Observed Plasma Concentration at Day 8, Time to Maximum Concentration at Day 8 and 4 more. Started Sep 2023; status: terminated.
02
Drugs
rezafungin
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT05534529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534529.